Voyager Therapeutics Q1 2022 Earnings Report
Key Takeaways
Voyager Therapeutics reported a net loss of $21.3 million for the first quarter of 2022, with collaboration revenue of $0.7 million. The company's cash, cash equivalents, and marketable debt securities totaled $166.8 million as of March 31, 2022, expected to fund operations into 2024. Voyager continued to advance its TRACER capsid discovery platform and pipeline programs, including a license option agreement with Novartis.
Executed license option agreement with Novartis for target-specific access to next-generation TRACER AAV capsids
Alfred W. Sandrock, Jr., M.D., Ph.D. appointed as Chief Executive Officer and Board Member
Cash runway into 2024
Voyager to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
Voyager Therapeutics
Voyager Therapeutics
Voyager Therapeutics Revenue by Segment
Forward Guidance
Voyager expects that its cash, cash equivalents, and marketable debt securities will be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2024.